NasdaqGS:IBRXBiotechs
The Bull Case For ImmunityBio (IBRX) Could Change Following EMA’s Conditional Backing Of ANKTIVA Therapy
ImmunityBio previously announced that the European Medicines Agency had recommended granting a conditional EU marketing authorization for ANKTIVA, in combination with BCG, to treat BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ based on a single-arm trial in 100 adults.
This marks the first EMA-recommended immunotherapy for this form of bladder cancer that activates NK cells, T cells, and memory T cells, potentially offering an alternative to radical surgery for...